Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Launched by DIPAN SHAH · Feb 15, 2017

Keywords

ClinConnect Summary

Gadolinium-containing contrast agents (GdCAs) are intravenous agents used for contrast enhancement with magnetic resonance imaging (MRI) and with magnetic resonance angiography (MRA). The GdCAs (gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid) have been in use for few decades for different types of MR scan varying from product to product, including liver, brain, and whole body scan.

Recently, there has been a great interest in employing contrast-related techniques to assess for fibrosis in the myocardium of the heart. As opposed to...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing clinically referred CMR.
• Exclusion Criteria:
• • 1. Patients who are unable to give informed consent.
• • 2. Individuals with severe claustrophobia.
• • 3. Individuals unable to lie flat for 90 minutes (the anticipated amount of time to complete the MRI procedure).
• • 4. Individuals who are pregnant.
• • 5. Patients with implants or pacemakers.
• • 6. Patients that have hypersensitivity to components of gadolinium.
• • 7. Patients with renal failure.
• • 8. Patients who had any trauma or surgery which may have left ferromagnetic material in the body.

Trial Officials